Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

34.64 +0.56 (+1.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,205,428
Open 35.50
Bid (Size) 34.00 (100)
Ask (Size) 35.20 (400)
Prev. Close 34.08
Today's Range 34.46 - 36.35
52wk Range 28.66 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CORT INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Corcept Therapeutics Incorporated Investors
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire

Performance

YTD
-9.3%
-9.3%
1 Month
+1.2%
+1.2%
3 Month
-59.3%
-59.3%
6 Month
-56.7%
-56.7%
1 Year
-40.9%
-40.9%

More News

Read More
Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating Growth and a Solid Financial Base ↗
Via Chartmill
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid
Via StockStory
Topics Credit Cards
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims
From Grabar Law Office
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox Before April 21, 2026
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox Before April 21, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
CORT ALERT: Deadline in Securities Class Action Lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) is April 21, 2026 - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
News headline image
CORT ALERT: Deadline in Securities Class Action Lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) is April 21, 2026 - Contact Kaplan Fox
Via NewMediaWire
Topics Lawsuit
News headline image
CORCEPT THERAPEUTICS CLASS ACTION DEADLINE: Kaplan Fox Encourages Corcept Therapeutics, Inc. (NASDAQ: CORT) Investors to Contact the Firm Before the Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
CORCEPT THERAPEUTICS CLASS ACTION DEADLINE: Kaplan Fox Encourages Corcept Therapeutics, Inc. (NASDAQ: CORT) Investors to Contact the Firm Before the Lead Plaintiff Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 34.64
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 03/20/26 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 4.02B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.